<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5710">
  <stage>Registered</stage>
  <submitdate>18/11/2014</submitdate>
  <approvaldate>18/11/2014</approvaldate>
  <nctid>NCT02301637</nctid>
  <trial_identification>
    <studytitle>Eeva System Imaging Study</studytitle>
    <scientifictitle>Prospective Observational Study Utilizing the Eeva System 2.2.1 for Ongoing Collection of Development and Validation Data</scientifictitle>
    <utrn />
    <trialacronym>PROSPECT</trialacronym>
    <secondaryid>2014-AUX-012</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Infertility</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - Eeva Test

Treatment: devices: Eeva Test
The Eeva System is indicated to provide adjunctive information on events occurring during the first two days of development that may predict further development to the blastocyst stage on Day 5 of development. This adjunctive information aids in the selection of embryo(s) for transfer on Day 3 when, following morphological assessment on Day 3, there are multiple embryos deemed suitable for transfer or freezing.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Adverse events and device malfunctions will be reported and summarized from the point of Eeva imaging through study exit.</outcome>
      <timepoint>36 months</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  At least 18 years of age

          -  Women undergoing in vitro fertilization treatment using their own eggs

          -  Fresh or Frozen Blastocyst (Day 5-6) transfer

          -  At least 5 diploid (2PN) embryos at fertilization check

          -  Willing to have all 2PN embryos imaged by Eeva

          -  Willing to comply with study protocol and procedures

          -  Willing to provide written informed consent</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Female</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  Freeze-all due to ovarian hyperstimulation syndrome (OHSS)

          -  Use of donor egg / gestational carrier

          -  Fertilization using surgically removed sperm

          -  History of cancer

          -  Assisted Hatching (AH) on Day 3</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/10/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>500</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Unknown status</recruitmentstatus>
    <anticipatedlastvisitdate>1/12/2015</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Iowa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Wellington</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Progyny, Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this clinical trial is to collect imaging data on embryos followed to
      blastocyst stage (Day 5-6) for ongoing development and validation of the Eeva System.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02301637</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Sheua Shen, MD</name>
      <address>Vice President, Scientific and Medical Affairs</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>